X4 Pharmaceuticals, Inc Annual Operating Income (Loss) in USD from 2016 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
X4 Pharmaceuticals, Inc quarterly/annual Operating Income (Loss) history and growth rate from 2016 to 2023.
  • X4 Pharmaceuticals, Inc Operating Income (Loss) for the quarter ending September 30, 2024 was -$34.5M, a 26.8% decline year-over-year.
  • X4 Pharmaceuticals, Inc Operating Income (Loss) for the twelve months ending September 30, 2024 was -$25.9M, a 76% increase year-over-year.
  • X4 Pharmaceuticals, Inc annual Operating Income (Loss) for 2023 was -$108M, a 22.8% decline from 2022.
  • X4 Pharmaceuticals, Inc annual Operating Income (Loss) for 2022 was -$87.6M, a 2.89% decline from 2021.
  • X4 Pharmaceuticals, Inc annual Operating Income (Loss) for 2021 was -$85.1M, a 42.1% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$108M -$20M -22.8% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-21
2022 -$87.6M -$2.46M -2.89% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-21
2021 -$85.1M -$25.2M -42.1% Jan 1, 2021 Dec 31, 2021 10-K 2024-03-21
2020 -$59.9M -$8.17M -15.8% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-21
2019 -$51.7M -$22.6M -77.8% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-17
2018 -$29.1M -$6.84M -30.7% Jan 1, 2018 Dec 31, 2018 10-K 2021-03-19
2017 -$22.2M +$2.1M +8.62% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-12
2016 -$24.3M Jan 1, 2016 Dec 31, 2016 10-K 2019-03-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.